Minneapolis, MN – December 11, 2017 – Rimage Corporation, a global leader in optical media publishing, announced today that it has added a new generation to the Producer™ series – the Rimage Producer V disc publishing system. The Producer series is the most powerful line of disc publishing systems from Rimage, engineered for 24×7 performance.
Rimage® Announces Newest Generation in the Producer Series – Producer™ V
Computer Science Education Week is here!
Computer Science Education Week is this week, December 4-10, 2017. The week is dedicated to inspiring K-12 students to take interest in computer science, and was chosen to recognize the birthday of computing pioneer Admiral Grace Murray Hopper (December 9, 1906).
Lt. Governor Tina Smith, Department of Employment and Economic Development Announce $26 Million for 39 Broadband Projects Across Greater Minnesota
New round of grants will expand high-speed internet access to 9,973 households, 2,169 businesses, and 60 community institutions in Greater Minnesota. New state grant funding will leverage an additional $34 million in private and local funding. State grant program has invested a total of $85 million, provided 33,852 households, 5,189 businesses, and 300 community institutions broadband access since 2014.
AT&T Plans to Launch 5G Evolution in Minneapolis in Time for Big Game
MHTA – AT&T has announced that they plan to launch 5G Evolution in parts of Minneapolis in the coming months. It will provide its latest network technology in some parts of the city, including areas near the host stadium, in time for the Big Game in February.
Exxell BIO joins collaboration among research institutions, private industry, and the US Government to develop a Novel Vaccine for Ebola and other Hemorrhagic Fever Viruses
ST. PAUL & ROCHESTER, MINN— Exxell BIO, with offices in St. Paul and Rochester, Minnesota, is part of a new consortium formed to prepare and test a vaccine formulation designed to protect against the Ebola, Sudan, Marburg, and Lassa fever viruses. Exxell BIO worked with Thomas Jefferson University (TJU) in the development of a TJU-led consortium for this major vaccine program. The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH) has made an initial award of approximately $2.6 million to Thomas Jefferson University with further funding of up to a total of $30 million available over the course of the contract if all contract options are exercised. This five‐year contract, with the goal of completing a Phase 1 clinical trial of the tetravalent vaccine, will be funded by NIAID under Contract No. HHSN272201700082C.